FedCircuitBlog

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:

• an article about a $948 million patent infringement verdict between Intel and VLSI Technology LLC;
• another article about a Federal Circuit decision finding a generic cancer drug infringes on “Abbvie’s Pharmacyclics and Johnson & Johnson’s Janssen Biotech . . . blockbuster cancer drug Imbruvica”; and
• a blog post about a Federal Circuit decision affirming the Patent Trial and Appeal Board’s decision “involving American National Manufacturing and Sleep Number Corp.”

This morning the Federal Circuit released a precedential opinion in a patent case appealed from the Patent Trial and Appeal Board. In this opinion, the Federal Circuit affirms the Board’s decision that specific claims are unpatentable, reversed the Board’s construction of the phrase “used for electrical interconnection,” and remanded the case. The Federal Circuit also released three nonprecedential opinions. The first comes in a case appealed from the Merit Systems Protection Board; the second comes in a patent case appealed from the District of Delaware; and the third comes in a government contract case appealed from the Court of Federal Claims. Finally, the Federal Circuit released two nonprecedential orders. One transfers an appeal to the Court of Appeals for the Second Circuit, and one transfers an appeal to the District of Maryland.

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:

• an article about two recent rulings by the Federal Circuit that may “dent the number of Section 101 motions to dismiss that courts fully or partially grant each year”;
• another article about a Federal Circuit case that would “clear the way for a proposed generic” opioid drug; and
• a blog post about a decision in which the Federal Circuit held “the definition of a claim term in a patent incorporated by reference into the patents at issue does not dictate the definition of claims in the asserted patents.”